Thermo Fisher Scientific Inc. (TMO) receives a strong valuation score of 98 from InvestorsObserver's analysis. Our proprietary scoring system considers the overall health of the company by looking at the stock's price, earnings, and growth rate to determine if it represents a good value. TMO holds a better value than 98% of stocks at its current price. Investors who are focused on long-term growth through buy-and-hold investing will find the Valuation Rank especially relevant when allocating their assets.
TMO's trailing-12-month Price to Earnings (PE) ratio of 22.6 puts it above the historical average of roughly 15. TMO is a poor value at its current trading price as investors are paying more than what its worth in relation to the company's earnings. TMO's trailing-12-month earnings per share (EPS) of 19.87 does not justify what it is currently trading at in the market. Trailing PE ratios, however, do not factor in a company's projected growth rate, resulting in some firms having high PE ratios due to high growth potentially enticing investors even if current earnings are low.
TMO currently has a 12-month-forward-PE-to-Growth (PEG) ratio of 1.03. The market is currently fairly valuing TMO in relation to its projected growth due to the PEG ratio being around the fair market value of 1. TMO's PEG comes from its forward price to earnings ratio being divided by its growth rate. Because PEG ratios include more fundamentals of a company's overall health with additional focus on the future, they are one of the most used valuation metrics by analysts.
TMO' has a adequate valuation at its current share price on account of a fairly valued PEG ratio despite strong growth. TMO's PE and PEG are around the market average leading to a average valuation score.